ACADIA PHARMACEUTICALS INC. Additional Paid in Capital, Common Stock
ACADIA PHARMACEUTICALS INC. (ACAD) had Additional Paid in Capital, Common Stock of $3.09 billion as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-05
- 2026-06-30: Additional Paid in Capital, Common Stock $3.09B.
- 2026-03-31: Additional Paid in Capital, Common Stock $3.06B.
- 2025-12-31: Additional Paid in Capital, Common Stock $3.04B.
- 2025-09-30: Additional Paid in Capital, Common Stock $3.00B.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2026-06-30 | $3.09B 10-Q · filed 2026-08-05 |
| 2026-03-31 | $3.06B 10-Q · filed 2026-05-07 |
| 2025-12-31 | $3.04B 10-Q · filed 2026-08-05 |
| 2025-09-30 | $3.00B 10-Q · filed 2025-11-06 |
| 2025-06-30 | $2.98B 10-Q · filed 2025-08-07 |
| 2025-03-31 | $2.95B 10-Q · filed 2025-05-08 |
| 2024-12-31 | $2.94B 10-K · filed 2026-02-26 |
| 2024-09-30 | $2.92B 10-Q · filed 2024-11-07 |
| 2024-06-30 | $2.90B 10-Q · filed 2024-08-07 |
| 2024-03-31 | $2.88B 10-Q · filed 2024-05-09 |
| 2023-12-31 | $2.86B 10-K · filed 2025-02-27 |
| 2023-09-30 | $2.84B 10-Q · filed 2023-11-03 |
| 2023-06-30 | $2.81B 10-Q · filed 2023-08-03 |
| 2023-03-31 | $2.79B 10-Q · filed 2023-05-08 |
| 2022-12-31 | $2.77B 10-K · filed 2024-02-28 |
| 2022-09-30 | $2.75B 10-Q · filed 2022-11-03 |
| 2022-06-30 | $2.74B 10-Q · filed 2022-08-09 |
| 2022-03-31 | $2.71B 10-Q · filed 2022-05-05 |
| 2021-12-31 | $2.69B 10-K · filed 2023-02-28 |
| 2021-09-30 | $2.68B 10-Q · filed 2021-11-09 |
| 2021-06-30 | $2.66B 10-Q · filed 2021-08-05 |
| 2021-03-31 | $2.63B 10-Q · filed 2021-05-06 |
| 2020-12-31 | $2.61B 10-K · filed 2022-03-01 |
| 2020-09-30 | $2.57B 10-Q · filed 2020-11-04 |
| 2020-06-30 | $2.50B 10-Q · filed 2020-08-06 |
| 2020-03-31 | $2.43B 10-Q · filed 2020-05-08 |
| 2019-12-31 | $2.40B 10-K · filed 2021-02-25 |
| 2019-09-30 | $2.34B 10-Q · filed 2019-10-31 |
| 2019-06-30 | $2.00B 10-Q · filed 2019-08-01 |
| 2019-03-31 | $1.97B 10-Q · filed 2019-05-02 |
| 2018-12-31 | $1.95B 10-K · filed 2020-02-27 |
| 2018-09-30 | $1.63B 10-Q · filed 2018-11-06 |
| 2018-06-30 | $1.61B 10-Q · filed 2018-08-08 |
| 2018-03-31 | $1.58B 10-Q · filed 2018-05-04 |
| 2017-12-31 | $1.56B 10-K · filed 2019-02-27 |
| 2017-09-30 | $1.53B 10-Q · filed 2017-11-07 |
| 2017-06-30 | $1.50B 10-Q · filed 2017-08-08 |
| 2016-12-31 | $1.45B 10-K · filed 2018-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |